Cardiovascular Associates
Birmingham, Alabama, 35209, United States
NCT Number: NCT00479024
To determine comparative 1-year outcomes in renally impaired patients who previously underwent cardiac angiography with Isovue®-370 or Visipaque™ 320 as part of the IOP-104 trial protocol and were evaluable for determination of post-contrast significant renal injury (defined as >25% increase in SCr or >25% increase in cystatin C).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Birmingham, Alabama, 35209, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(from previous CARE trial)
Exclusion criteria
iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
Bracco Diagnostics, Inc
Industry
CARE (Visipaque 320 and Isovue 370 in Cardiac Angiography in REnally Impaired Patients); FOLLOW-UP STUDY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02933827
Moderate to Severe Chronic Kidney Disease
New Taipei City, Taiwan
View Trial Details